natgillin/translations-raw huggingface dataset:
At least eleven amino acid sites in the protease have been associated with indinavir resistance: L10, K20, L24, M46, I54, L63, I64, A71, V82, I84, and L90. 
Postoji najmanje jedanaest aminokiselinskih mjesta na proteazi koja se povezuju s rezistencijom na indinavir: L10, K20, L24, M46, I54, L63, I64, A71, V82, I84 i L90.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolesnici s rijetkim nasljednim problemima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcijom glukoze i galaktoze ne bi trebali uzimati ovaj lijek.
In addition, talk to your doctor, pharmacist or nurse before taking CRIXIVAN if you are taking any of the following medicines since your doctor may want to adjust the dose of your medicines: 
Nadalje, obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete CRIXIVAN ako uzimate neki od sljedećih lijekova jer će liječnik možda htjeti prilagoditi dozu Vaših lijekova:
In addition, when CRIXIVAN is given at the same time as the medicine ritonavir: Do not take either CRIXIVAN or ritonavir: 
Nadalje, kada se CRIXIVAN primjenjuje istodobno s ritonavirom: Nemojte uzimati ni CRIXIVAN niti ritonavir:
No carcinogenicity was noted in mice at the maximum tolerated dose, which corresponded to a systemic exposure approximately 2 to 3 times higher than the clinical exposure. 
U miševa nije primijećena kancerogenost kod najviše podnošljive doze koja odgovara sustavnoj izloženosti otprilike 2 do 3 puta većoj od kliničke izloženosti.
What CRIXIVAN is and what it is used for 
Što je CRIXIVAN i za što se koristi
Please see ‘Do not take CRIXIVAN' and ‘Do not take either CRIXIVAN or ritonavir' above under Section 2 for an important list of medicines that you must not combine with CRIXIVAN. 
Molimo pročitajte odjeljke ‘Nemojte uzimati CRIXIVAN' i ‘Nemojte uzimati CRIXIVAN niti ritonavir' u dijelu 2 u kojima ćete pronaći važan popis lijekova koje ne smijete kombinirati s lijekom CRIXIVAN.
Distribution of indinavir across the placental barrier was significant in rats, but limited in rabbits. 
Raspodjela indinavira kroz placentalnu barijeru bila je značajna u štakora, ali ograničena u kunića.
• feeling numb or unusual feeling of the skin. 
• utrnulost ili neuobičajen osjet na koži.
Store CRIXIVAN in the original bottle and keep the bottle tightly closed to protect it from moisture. 
Čuvajte CRIXIVAN u originalnoj bočici, a bočicu čuvajte čvrsto zatvorenu radi zaštite od vlage.
Developmental Toxicity 
Razvojna toksičnost
• If you cannot take it without food then take CRIXIVAN with a low-fat light meal. 
• Ako ga ne možete uzeti bez hrane, uzmite CRIXIVAN s laganim obrokom siromašnim mastima.
Inform your doctor as soon as possible if you develop severe muscle pain or weakness. 
Što prije obavijestite liječnika ako osjetite jaku bol ili slabost u mišićima.
Developmental toxicity studies were performed in rats, rabbits and dogs (at doses which produced systemic exposures comparable to or slightly greater than human exposure) and revealed no evidence of teratogenicity. 
Istraživanja razvojne toksičnosti provedena su na štakorima, kunićima i psima (pri dozama koje izazivaju sustavnu izloženost sličnu ili malo veću od izloženosti u ljudi) i nisu otkriveni znakovi teratogenosti.
• if you have liver problems 
• ako imate tegoba s jetrom
• The active substance is indinavir. 
• Djelatna tvar je indinavir.
• severe pain, tenderness or weakness in your muscles - this is more likely to happen if you are taking cholesterol-lowering medicines called ‘statins' (such as simvastatin). 
• jaku bol, osjetljivost ili slabost mišića - pojava ovih simptoma je vjerojatnija ako uzimate lijekove za snižavanje kolesterola koji se nazivaju ‘statinima' (poput simvastatina).
Do not use this medicine after the expiry date which is stated on the bottle or carton after ‘EXP'. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na bočici ili kutiji iza oznake ‘Rok valjanosti'.
How CRIXIVAN works CRIXIVAN treats HIV and helps to lower the number of HIV particles in your blood. 
Kako djeluje CRIXIVAN CRIXIVAN liječi HIV infekciju i pomaže smanjiti broj HIV čestica u krvi.
• darkening skin colour 
• tamnija boja kože
SEDATIVES/HYPNOTICS Midazolam (parenteral) 
SEDATIVI/HIPNOTICI Midazolam (parenteralno)
• blood in your urine. 
• krv u mokraći.
Indinavir did not significantly inhibit the eukaryotic proteases human renin, human cathepsin D, human elastase, and human factor Xa. 
Indinavir nije značajno inhibirao eukariotske proteaze humani renin, humani katepsin D, humanu elastazu ni humani faktor Xa.
Caution is warranted and clinical monitoring of patients is recommended. 
Nužan je oprez i preporučuje se klinički nadzor bolesnika.
PDE5 INHIBITOR Sildenafil, tadalafil 
INHIBITORI PDE5 Sildenafil, tadalafil
Most patients continued treatment with CRIXIVAN without dose reduction and bilirubin values gradually declined toward baseline. 
Većina bolesnika nastavila je liječenje lijekom CRIXIVAN bez smanjenja doze, a vrijednosti bilirubina postupno su se smanjivale prema početnim vrijednostima.
Similarly, indinavir might also modify the pharmacokinetics of other substances that share this metabolic pathway. 
Isto tako indinavir može izmijeniti farmakokinetiku drugih tvari koje dijele isti metabolički put.
Many of these adverse reactions were also identified as common pre-existing or frequently occurring medical conditions in this population. 
Za mnoge od tih nuspojava utvrđeno je i da obično otprije postoje ili se često javljaju u navedenoj populaciji.
The relevance of these findings for ritonavir boosted indinavir is unknown. 
Značaj tih rezultata za primjenu indinavira pojačanog ritonavirom nije poznata.
• tacrolimus, ciclosporin - used mainly after organ transplantation 
• takrolimus, ciklosporin - uglavnom se koriste nakon transplatacije organa
Adequate hydration is recommended in all patients on indinavir (see sections 4.2 and 4.8). 
U svih bolesnika koji uzimaju indinavir preporučuje se odgovarajuća hidratacija (vidjeti dijelove 4.2 i 4.8).
Common (affects less than 1 in 10 people): 
Česte (javljaju se u manje od 1 na 10 osoba)
This will help lower the risk of you getting kidney stones. 
Time će se umanjiti rizik od stvaranja bubrežnih kamenaca.
Very common (≥ 1/10); Common (≥ 1/100 to  1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to  1/1,000); Very rare (< 1/10,000); not known (cannot be estimated from the available data). 
Vrlo često (≥ 1/10), često (≥ 1/100 i  1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i  1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The safety and efficacy of CRIXIVAN in children under the age of 4 years have not been established (see sections 5.1 and 5.2). 
Sigurnost i djelotvornost lijeka CRIXIVAN u djece mlađe od 4 godine nisu ustanovljene (vidjeti dijelove 5.1 i 5.2).
A causal relationship has been evoked, although the mechanism of action has not been elucidated. 
Pretpostavlja se da postoji uzročna povezanost iako mehanizam djelovanja nije rasvijetljen.
Adverse reactions, including nephrolithiasis, may lead to treatment interruption. 
Nuspojave, uključujući nefrolitijazu, mogu dovesti do prekida liječenja.
If persistent severe leucocyturia is found, further investigation might be warranted. 
Ako se utvrdi dugotrajna i teška leukociturija, mogu biti potrebne dodatne pretrage.
CRIXIVAN is used to treat Human Immunodeficiency Virus (HIV) in adults. 
CRIXIVAN se koristi za liječenje infekcije virusom humane imunodeficijencije (HIV) u odraslih.
The suggestion is based on limited published data (see section 5.2). 
Taj se prijedlog temelji na ograničenom broju objavljenih podataka (vidjeti dio 5.2).
What you need to know before you take CRIXIVAN 
Što morate znati prije nego počnete uzimati CRIXIVAN
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. 
Pojave li se u tih bolesnika znakovi pogoršanja bolesti jetre, treba razmotriti privremen ili trajan prekid liječenja.
Dose reduction of rifabutin and dose increase of Crixivan has not been confirmed in clinical studies. 
Smanjenje doze rifabutina i povećanje doze lijeka CRIXIVAN nije potvrđeno kliničkim ispitivanjima.
The risk of you having bone problems is higher if you: - drink alcohol - have a high body mass index - have an immune system that is very weak - have been taking corticosteroids at the same time as CRIXIVAN - take combination antiretroviral therapy for a long time. 
Vjerojatnost da ćete imati tegoba s kostima veća je ako: - pijete alkohol - imate visok indeks tjelesne mase - imate vrlo oslabljen imunološki sustav - uzimate kortikosteroide istodobno s lijekom CRIXIVAN - dugotrajno primate kombinirano antiretrovirusno liječenje.
Therefore, therapy with indinavir should be initiated at the recommended dose to increase suppression of viral replication and therefore inhibit the emergence of resistant virus. 
Stoga se liječenje indinavirom mora započeti preporučenom dozom kako bi se pojačala supresija replikacije virusa i tako inhibirala pojava rezistentnih sojeva virusa.
Many of the protease amino acid substitutions reported to be associated with resistance to ritonavir and saquinavir were also associated with resistance to indinavir. 
Mnoge aminokiselinske supstitucije na proteazi za koje je prijavljeno da su povezane s rezistencijom na ritonavir i sakvinavir također su bile povezane i s rezistencijom na indinavir.
Also some other medicines can affect the way CRIXIVAN works. 
Isto tako neki drugi lijekovi mogu utjecati na način djelovanja lijeka CRIXIVAN.
Studies in rats indicated that uptake into brain tissue was limited, distribution into and out of the lymphatic system was rapid, and excretion into the milk of lactating rats was extensive. 
Istraživanja na štakorima pokazala su da je pohrana u moždano tkivo ograničena, raspodjela u limfni sustav i iz limfnog sustava brza, a izlučivanje u mlijeko ženki štakora u laktaciji opsežno.
There are no data to suggest that indinavir affects the ability to drive and use machines. 
Nema podataka koji bi pokazali da indinavir utječe na sposobnost upravljanja vozilima i rada na strojevima.
• sildenafil, vardenafil, tadalafil - used for impotence 
• sildenafil, vardenafil, tadalafil - koriste se za impotenciju
Two clinical trials in 41 paediatric patients (4 to 15 years of age) were designed to characterise the safety, antiretroviral activity, and pharmacokinetics of indinavir in combination with stavudine and lamivudine. 
Dva klinička ispitivanja u kojima je sudjelovao 41 pedijatrijski bolesnik (u dobi od 4 do 15 godina) osmišljena su s ciljem utvrđivanja sigurnosti, antiretrovirusnog djelovanja i farmakokinetike indinavira u kombinaciji sa stavudinom i lamivudinom.
On the basis of current pharmacodynamic data, indinavir must be used in combination with other antiretroviral agents. 
Prema postojećim farmakodinamičkim podacima, indinavir se mora primjenjivati u kombinaciji s drugim antiretrovirusnim lijekovima.
Crixivan, 800 mg every 8 hours + zidovudine 200 mg every 8 hours and lamivudine 150 mg twice a day). 
Crixivan, 800 mg svakih 8 sati + zidovudin 200 mg svakih 8 sati i lamivudin 150 mg dvaput na dan).
Data from a steady state study in healthy volunteers indicate that there is a diurnal variation in the pharmacokinetics of indinavir. 
Podaci iz ispitivanja lijeka u stanju dinamičke ravnoteže u zdravih dobrovoljaca pokazuju dnevne varijacije u farmakokinetici indinavira.
• Swallow the capsules whole with a drink of water, skimmed or low fat milk, juice, tea or coffee. 
• Kapsule progutajte cijele s vodom, obranim ili nemasnim mlijekom, sokom, čajem ili kavom.
In the absence of such studies, caution should be exercised as increased levels of indinavir may occur. 
Zbog nedostatka takvih ispitivanja preporučuje se oprez jer može doći do povišenih koncentracija indinavira.
Once a diagnosis is apparent, appropriate measures for the treatment of haemolytic anaemia should be instituted which may include discontinuation of indinavir. 
Kada se postavi jasna dijagnoza, treba uvesti odgovarajuće mjere za liječenje hemolitičke anemije, među kojima može biti prekid liječenja indinavirom.
The bioavailability of a single 800-mg dose of indinavir was approximately 65 % (90 % CI, 58 - 72 %). 
Bioraspoloživost jedne doze indinavira od 800 mg iznosila je približno 65% (90% CI, 58 - 72%).
Six of these 11 (55 %) patients had mean indinavir plasma concentrations 8 hours postdose (Cmin) below assay threshold of reliable quantification. 
U 6 od navedenih 11 (55%) bolesnica srednje koncentracije indinavira u plazmi 8 sati nakon primjene doze (Cmin) bile su ispod granice pouzdane mjerljivosti.
Combination not recommended 
Ova kombinacija se ne preporučuje.
HMG-CoA REDUCTASE INHIBITORS Lovastatin, simvastatin 
INHIBITORI HMG-CoA REDUKTAZE Lovastatin, simvastatin
Patients with severe hepatic impairment have not been studied; therefore, no dosing recommendations can be made (see section 4.4). 
Bolesnici s teškim oštećenjem funkcije jetre nisu ispitivani, stoga se ne može dati preporuka za doziranje (vidjeti dio 4.4).
It should be noted that the decrease in suppression of viral RNA levels was seen more frequently when therapy with indinavir was initiated at doses lower than the recommended oral dose of 2.4 g/day. 
Treba napomenuti da je smanjenje supresije virusne RNK primijećeno češće kad je liječenje indinavirom započelo nižim dozama od preporučene peroralne doze od 2,4 g na dan.
The recommended dose of CRIXIVAN is: 
Preporučena doza lijeka CRIXIVAN je:
No formal interaction study has been performed. 
Nije provedeno službeno ispitivanje interakcija.
Atazanavir as well as indinavir are associated with indirect (unconjugated) hyperbilirubinemia due to inhibition of UDP-glucuronosyltransferase (UGT). 
Atazanavir se, kao i indinavir, povezuje s indirektnom (nekonjugiranom) hiperbilirubinemijom koja nastaje zbog inhibicije UDP-glukuronoziltransferaze (UGT).
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products. 
U slučaju istodobne primjene antiretrovirusnih lijekova za liječenje hepatitisa B ili C treba proučiti informacije o lijeku i za te lijekove.
This proportion tends to remain stable over prolonged periods of follow-up. 
Taj se udio u načelu održao stabilnim tijekom dugotrajnih razdoblja praćenja.
• autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. 
• autoimuni poremećaji (stanje koje se javlja kada imunološki sustav napada zdravo tkivo u tijelu) mogu se javiti nakon što počnete uzimati lijekove za liječenje HIV infekcije.
Administration of indinavir to pregnant Rhesus monkeys during the third trimester did not cause a similar exacerbation in neonates; however, only limited placental transfer of indinavir occurred. 
Primjena indinavira skotnim ženkama rezus majmuna tijekom trećega tromjesečja nije izazvala sličnu egzacerbaciju u novorođenčadi, međutim, došlo je samo do ograničenog prijenosa indinavira kroz placentu.
It is recommended that HIV infected women do not breast feed their infants under any circumstances in order to avoid transmission of HIV. 
Preporučuje se da žene zaražene HIV-om ni pod kojim uvjetom ne doje svoju novorođenčad kako bi se izbjegao prijenos HIV-a.
During attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with ritonavir, a high frequency of liver reactions was seen. 
Kod pokušaja prevladavanja smanjene izloženosti povećanjem doze drugih inhibitora proteaze s ritonavirom primijećena je visoka učestalost jetrenih reakcija.
Pharmacotherapeutic group: Antivirals for systemic use, protease inhibitor, ATC code JO5AE02 
Farmakoterapijska skupina: lijekovi za liječenje sustavnih virusnih infekcija, inhibitori proteaze, ATK oznaka JO5AE02
Less than 20 % of indinavir is excreted renally. 
Manje od 20% indinavira izlučuje se bubrezima.
• atorvastatin, rosuvastatin, pravastatin, fluvastatin - used to lower cholesterol 
• atorvastatin, rosuvastatin, pravastatin, fluvastatin - koriste se za snižavanje kolesterola
At week 4, the indinavir Cmin was 500 ng/mL with substantial trough variability (range 5 to 8,100 ng/mL). 
U 4. je tjednu Cmin indinavira bio 500 ng/ml, sa značajnom varijabilnošću (raspon od 5 do 8100 ng/ml).
Resistance was correlated with the accumulation of mutations in the viral genome that resulted in the expression of amino acid substitutions in the viral protease. 
Rezistencija je bila u korelaciji s akumulacijom mutacija virusnoga genoma koje su dovele do ekspresije aminokiselinskih supstitucija u virusnoj proteazi.
In rats and rabbits, no effects on embryonic/foetal survival or foetal weights were observed. 
U štakora i kunića nisu primijećeni učinci na preživljenje embrija/fetusa niti na težinu ploda.
The recommendation is based on limited pharmacokinetic data (see section 5.2). 
Ova se preporuka temelji na malobrojnim farmakokinetičkim podacima (vidjeti dio 5.2).
Hyperbilirubinaemia occurred more frequently at doses exceeding 2.4 g/day compared to doses less than 2.4 g/day. 
Hiperbilirubinemija se češće javljala pri dozama višima od 2,4 g na dan u odnosu na doze niže od 2,4 g na dan.
Analysis of plasma and urine samples from subjects who received indinavir indicated that indinavir metabolites had little proteinase inhibitory activity. 
Analiza uzoraka plazme i mokraće ispitanika koji su primili indinavir pokazala je da metaboliti indinavira imaju slab inhibitorni učinak na proteinazu.
There are also other side effects that you may get while taking this medicine such as increased bleeding in haemophiliacs, muscle problems, signs of infection, and bone problems. 
Postoje i druge nuspojave koje se mogu javiti kod uzimanja ovog lijeka, poput pojačanog krvarenja u bolesnika s hemofilijom, tegoba s mišićima, znakova infekcije i tegoba s kostima.
Dose modification of calcium channel blockers should be considered when coadministered with indinavir/ritonavir as it may result in an increased response. 
Treba razmotriti prilagodbu doze blokatora kalcijevih kanala kad se primjenjuju istodobno s indinavirom/ritonavirom jer može doći do pojačanog odgovora.
CRIXIVAN is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults. 
CRIXIVAN je u kombinaciji s antiretrovirusnim nukleozidnim analozima indiciran za liječenje odraslih bolesnika zaraženih virusom HIV-1.
Therefore, other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of indinavir. 
Stoga, druge tvari koje dijele isti metabolički put ili mijenjaju aktivnost CYP3A4 mogu utjecati na farmakokinetiku indinavira.
If you take more CRIXIVAN than you should 
Ako uzmete više lijeka CRIXIVAN nego što ste trebali
Do not take either CRIXIVAN or ritonavir if any of the above applies to you. 
Nemojte uzimati ni CRIXIVAN niti ritonavir ako se nešto od gore navedenog odnosi na Vas.
The observed amino acid substitutions appeared to accumulate sequentially and in no consistent order, probably as a result of ongoing viral replication. 
Čini se da se opažene aminokiselinske supstitucije akumuliraju jedna za drugom bez ustaljenog redoslijeda, najvjerojatnije kao posljedica neprekidne replikacije virusa.
The design of the study does not allow for definitive evaluation of the effect of saquinavir on indinavir, but suggests there is less than a two-fold increase in indinavir AUC8h during co-administration with saquinavir 
Dizajn ispitivanja ne omogućuje konačnu ocjenu učinka sakvinavira na indinavir, ali pokazuje da kod istodobne primjene sa sakvinavirom dolazi do manje od dvostrukog povećanja AUC8h indinavira.
This could be dry toast with jam or cornflakes with skimmed or low-fat milk and sugar. 
To može biti prepečenac s marmeladom ili kukuruzne pahuljice s obranim ili nemasnim mlijekom i šećerom.
These adverse reactions were: nausea (35.3 %), headache (25.2 %), diarrhoea (24.6 %), asthenia/fatigue (24.3 %), rash (19.1 %), taste perversion (19.1 %), dry skin (16.2 %), abdominal pain (14.6 %), vomiting (11.0 %), dizziness (10.7 %). 
Te su nuspojave bile mučnina (35,3%), glavobolja (25,2%), proljev (24,6%), astenija/umor (24,3%), osip (19,1%), promjena osjeta okusa (19,1%), suha koža (16,2%), bol u abdomenu (14,6%), povraćanje (11,0%), omaglica (10,7%).
Nephrolithiasis has occurred with indinavir therapy in adult patients with a cumulative frequency of 12.4 % (range across individual trials: 4.7 % to 34.4 %). 
Tijekom liječenja indinavirom nefrolitijaza se u odraslih bolesnika javljala s ukupnom učestalošću od 12,4% (raspon između pojedinačnih ispitivanja: 4,7% do 34,4%).
Administration with light meals (e.g., dry toast with jam or fruit conserve, apple juice, and coffee with skimmed or fat-free milk and sugar or corn flakes, skimmed or fat-free milk and sugar) resulted in plasma concentrations comparable to the corresponding fasted values. 
Primjena uz lagane obroke (npr. prepečenac s marmeladom ili džemom od voća, jabučni sok i kava s obranim ili nemasnim mlijekom i šećerom ili kukuruzne pahuljice s obranim ili nemasnim mlijekom i šećerom) dovela je do koncentracija u plazmi koje su bile slične vrijednostima natašte.
Eighteen patients completed the study to week 48. 
Osamnaest je bolesnika dovršilo 48 tjedana ispitivanja.
• This is because reducing or missing doses will make it more likely that HIV will become resistant to CRIXIVAN. 
• Naime, smanjenje ili propuštanje doze povećava vjerojatnost da će HIV razviti otpornost na
It is not known whether indinavir is dialyzable by peritoneal or haemodialysis. 
Nije poznato može li se indinavir ukloniti peritonealnom dijalizom ili hemodijalizom.
In controlled clinical trials conducted world-wide, indinavir was administered alone or in combination with other antiretroviral agents (zidovudine, didanosine, stavudine, and/or lamivudine) to approximately 2,000 patients, the majority of whom were adult Caucasian males (15 % females). 
U kontroliranim kliničkim ispitivanjima provedenima diljem svijeta indinavir je primjenjivan samostalno ili u kombinaciji s drugim antiretrovirusnim lijekovima (zidovudin, didanozin, stavudin i/ili lamivudin) u približno 2000 bolesnika, od kojih su većina bili odrasli muškarci bijele rase (15% žena).
Loss of suppression of viral RNA levels occurred in some patients; however, CD4 cell counts were often sustained above pre-treatment levels. 
U nekih je bolesnika došlo do gubitka supresije virusne RNK, međutim, broj CD4 stanica se često održao na višoj razini nego prije liječenja.
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). 
Iako se smatra da ima više uzroka (uključujući uzimanje kortikosteroida, konzumiranje alkohola, tešku imunosupresiju, povećan indeks tjelesne mase), osteonekroza je prijavljena posebno u bolesnika s uznapredovalom HIV bolešću i/ili u bolesnika na dugotrajnoj kombiniranoj antiretrovirusnoj terapiji.
Rifampicin is a strong CYP3A4 inducer and has been shown to cause a 92 % decrease in indinavir AUC which can result in virological failure and resistance development. 
Rifampicin je snažan induktor CYP3A4 koji može sniziti AUC indinavira za 92% te tako dovesti do virološkog neuspjeha i razvoja rezistencije.